Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials

Research output: Contribution to journalReviewResearchpeer-review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Authors' reply

    Research output: Contribution to journalComment/debateResearch

  3. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. TORS Base-of-Tongue Mucosectomy in Human Papilloma Virus-Negative Carcinoma of Unknown Primary

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Penetrating Orbital Sphenoid Sinus Trauma with a Wooden Stick: A Challenging Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Danish registry study showed increased incidence of paediatric haemangiomas and congenital vascular malformations from 1996 to 2015

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

OBJECTIVES: This systematic review provides an overview of the current clinical trials investigating therapeutic vaccines for HPV+ head and neck cancer and discusses the future directions of therapeutic vaccine therapy.

MATERIALS AND METHODS: A systematic search was conducted in PubMed, EMBASE, Cochrane and clinicaltrials.gov for clinical trials involving therapeutic vaccines. We included studies initiated between 2000 and 2018 with patients diagnosed with HPV+ head and neck cancer and extracted data concerning type of vaccine therapy, adverse events, immunogenicity and clinical outcome measures (e.g. tumour response, progression-free survival and overall survival).

RESULTS: We identified 11 studies (n = 376 patients) initiated between year 2005 and 2017. Four studies (n = 34) presented preliminary results in patients with incurable, recurrent loco-regional or distant metastatic disease indicating a positive immune response with 74% (n = 25/34 patients) having elevated antibody levels, IFN-γ and/or T-cell response. Five studies presented data on the vaccines' safety profile, demonstrating predominantly grade 1 and 2 toxicity. Three studies evaluated the clinical outcome - one study showed no complete or partial response, one study demonstrated stable disease as the best tumour response in 64% (n = 9/14 patients) and one study showed a 33% overall response rate: one patient with a complete response and seven patients with a partial response.

CONCLUSIONS: Treatment with therapeutic vaccines is a promising and seemingly safe strategy for patients with HPV+ head and neck cancer. However, there are not enough data to draw any further conclusions and clinical outcome measures and tumour responses to the vaccines are still missing.

Original languageEnglish
JournalVaccine
Volume36
Issue number45
Pages (from-to)6594-6605
Number of pages12
ISSN0264-410X
DOIs
Publication statusPublished - 29 Oct 2018

ID: 56133083